TY - CHAP M1 - Book, Section TI - Digoxin Use in Heart Failure A1 - Harper, Mariko W. A1 - Goldberger, Zachary D. A2 - Baliga, R. R. A2 - Abraham, William T. PY - 2018 T2 - Color Atlas and Synopsis of Heart Failure AB - In 1785, Sir William Withering first described the leaves from the common foxglove plant, Digitalis purpurea, as a treatment for heart failure (HF) and arrhythmia in his monograph “An Account of the Foxglove and Some of Its Medicinal Uses.”1 More than 200 years later, digoxin remains in contemporary use for the treatment of HF with reduced systolic function, albeit with increasing scrutiny and controversy. In 1997, the landmark Digitalis Investigation Group (DIG) trial showed that while digoxin did reduce total and HF-related hospitalizations, there was no survival benefit.2 Over the next decade, a change in practice patterns would lead to a significant reduction in digoxin use, but ultimately no change in the burden of digoxin-related adverse events.3,4 In patients with persistently symptomatic heart failure with reduced ejection fraction (HFrEF) on guideline-directed medical therapy, the addition of digoxin may help ameliorate signs and symptoms of HF, improve quality of life, and reduce overall and HF-specific hospitalizations. Thus, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the management of HF recommends digoxin as an adjuvant agent in select patient populations.5 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesscardiology.mhmedical.com/content.aspx?aid=1161018050 ER -